Michael David Smith - 01 Jun 2021 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
01 Jun 2021
Net transactions value
-$138,296
Form type
4
Filing time
03 Jun 2021, 18:28:22 UTC
Previous filing
28 May 2021
Next filing
19 May 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Options Exercise $62,925 +7,500 $8.39 7,500 01 Jun 2021 Direct
transaction KALV Common Stock Sale $201,221 -7,500 -100% $26.83 0 01 Jun 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Stock Option (right to buy) Options Exercise $0 -7,500 -25% $0.000000 22,596 01 Jun 2021 Common Stock 7,500 $8.39 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.22 to $27.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3 The option is fully vested.